These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

140 related items for PubMed ID: 39000058

  • 1. Benefits of NGS in Advanced Lung Adenocarcinoma Vary by Populations and Timing of Examination.
    Lee PH, Ou WF, Huang YH, Hsu KH, Tseng JS, Chang GC, Yang TY.
    Int J Mol Sci; 2024 Jun 25; 25(13):. PubMed ID: 39000058
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Liquid-based cytology specimens for next-generation sequencing in lung adenocarcinoma: challenges and evaluation of targeted therapy.
    Xiao X, Sun Z, Liang S, Li W, Guo H, Zhao H, Zhao L, Ma H, Sun Y, Wang C, Chang X, Zhang Z.
    BMC Cancer; 2024 Jun 20; 24(1):749. PubMed ID: 38902688
    [Abstract] [Full Text] [Related]

  • 5. Real-world utility of next-generation sequencing for targeted gene analysis and its application to treatment in lung adenocarcinoma.
    Kim JH, Yoon S, Lee DH, Jang SJ, Chun SM, Kim SW.
    Cancer Med; 2021 May 20; 10(10):3197-3204. PubMed ID: 33960703
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Comparison of targeted next-generation sequencing with conventional sequencing for predicting the responsiveness to epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy in never-smokers with lung adenocarcinoma.
    Han JY, Kim SH, Lee YS, Lee SY, Hwang JA, Kim JY, Yoon SJ, Lee GK.
    Lung Cancer; 2014 Aug 20; 85(2):161-7. PubMed ID: 24857785
    [Abstract] [Full Text] [Related]

  • 8. Next Generation Sequencing of Advanced Non-Small Cell Lung Cancer: Utilization Based on Race and Impact on Survival.
    Al-Ahmadi A, Ardeshir-Larijani F, Fu P, Cao S, Lipka MB, Dowlati A, Bruno DS.
    Clin Lung Cancer; 2021 Jan 20; 22(1):16-22.e1. PubMed ID: 33397584
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Next Generation Sequencing Analysis and its Benefit for Targeted Therapy of Lung Adenocarcinoma.
    Kulda V, Polivka J, Svaton M, Vanecek T, Buresova M, Houfkova K, Bagheri MS, Knizkova T, Vankova B, Windrichova J, Macan P, Babuska V, Pesta M.
    Cancer Genomics Proteomics; 2023 Jan 20; 20(4):404-411. PubMed ID: 37400146
    [Abstract] [Full Text] [Related]

  • 11. Economic Analysis of Exclusionary EGFR Test Versus Up-Front NGS for Lung Adenocarcinoma in High EGFR Mutation Prevalence Areas.
    Yang SC, Yeh YC, Chen YL, Chiu CH.
    J Natl Compr Canc Netw; 2022 Apr 06; 20(7):774-782.e4. PubMed ID: 35385830
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Prognostic value and therapeutic implications of expanded molecular testing for resected early stage lung adenocarcinoma.
    Kneuertz PJ, Carbone DP, D'Souza DM, Shilo K, Abdel-Rasoul M, Zhao W, Williams TM, Jones D, Merritt RE.
    Lung Cancer; 2020 May 06; 143():60-66. PubMed ID: 32208298
    [Abstract] [Full Text] [Related]

  • 14. Clinical outcomes of EGFR-TKI treatment and genetic heterogeneity in lung adenocarcinoma patients with EGFR mutations on exons 19 and 21.
    Yu JY, Yu SF, Wang SH, Bai H, Zhao J, An TT, Duan JC, Wang J.
    Chin J Cancer; 2016 Mar 21; 35():30. PubMed ID: 27001083
    [Abstract] [Full Text] [Related]

  • 15. Benefit of Targeted DNA Sequencing in Advanced Non-Small-Cell Lung Cancer Patients Without EGFR and ALK Alterations on Conventional Tests.
    Byeon S, Lee B, Park WY, Choi YL, Jung HA, Sun JM, Ahn JS, Ahn MJ, Park K, Lee SH.
    Clin Lung Cancer; 2020 May 21; 21(3):e182-e190. PubMed ID: 31839532
    [Abstract] [Full Text] [Related]

  • 16. Effectiveness of next-generation sequencing for patients with advanced non-small-cell lung cancer: a population-based registry study.
    Kang DW, Park SK, Yu YL, Lee Y, Lee DH, Kang S.
    ESMO Open; 2024 Jan 21; 9(1):102200. PubMed ID: 38194884
    [Abstract] [Full Text] [Related]

  • 17. Mutation Profile Assessed by Next-Generation Sequencing (NGS) of Circulating Tumor DNA (ctDNA) in Chinese Lung Adenocarcinoma Patients: Analysis of Real-World Data.
    Zhao S, Cong X, Liu Z.
    Biomed Res Int; 2021 Jan 21; 2021():8817898. PubMed ID: 33997043
    [Abstract] [Full Text] [Related]

  • 18. Molecular diagnostic characteristics based on the next generation sequencing in lung cancer and its relationship with the expression of PD-L1.
    Liu J, Liu Y.
    Pathol Res Pract; 2020 Feb 21; 216(2):152797. PubMed ID: 31926773
    [Abstract] [Full Text] [Related]

  • 19. Genomic Signature of Driver Genes Identified by Target Next-Generation Sequencing in Chinese Non-Small Cell Lung Cancer.
    Wen S, Dai L, Wang L, Wang W, Wu D, Wang K, He Z, Wang A, Chen H, Zhang P, Dong X, Dong YA, Wang K, Yao M, Wang M.
    Oncologist; 2019 Nov 21; 24(11):e1070-e1081. PubMed ID: 30902917
    [Abstract] [Full Text] [Related]

  • 20. Targeted Next-Generation Sequencing Reveals Exceptionally High Rates of Molecular Driver Mutations in Never-Smokers With Lung Adenocarcinoma.
    Mack PC, Klein MI, Ayers KL, Zhou X, Guin S, Fink M, Rossi M, Ai-Kateb H, O'Connell T, Hantash FM, Oh WK, Newman S, Schadt EE, Chen R, Hirsch FR.
    Oncologist; 2022 Jun 08; 27(6):476-486. PubMed ID: 35298662
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.